.... Myeloid malignancy gene mutational status in MN patients with RC. AML, acute myeloid leukemia; Chemo, chemotherapy; HMA, hypomethylating agent; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; VEN, venetoclax; VUS, variant of unknown significance. Table 1. Demographic...

...Karin Mayer; Leonie Birk; Katjana Schwab; Ingo G.H. Schmidt-Wolf; Marie von Lilienfeld-Toal; Peter Brossart; Axel Glasmacher; Corinna Hahn-Ast Introduction: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However...

...Jason S. Gilbert; Daniel A. Pollyea; Thomas J. Walsh; Andreas H. Groll; Hillard M. Lazarus Background: The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus...

...Junjie Cao; Xianxu Zhuang; Danjie Luo; Renzhi Pei; Ying Lu; Dong Chen; Shuangyue Li; Xiaohong Du; Xuhui Liu Introduction: The combination of venetoclax (VEN) and azacytidine (AZA) has demonstrated potential in achieving rapid and effective remissions in elderly patients with acute myeloid leukemia...

... and treatment adherence in patients with cancer. We report the outcomes of a pilot trial of a digital health coach intervention in patients with leukemia with the aim of improving self-efficacy. Methods: Adult patients with newly diagnosed acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) were...

...Jean Lachaine; Catherine Beauchemin; Fatéma Dodat; Yunghan Au; William K. Evans; Brian Leber; Kristjan Paulson; Andre Schuh; John Storring Introduction: Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated...

...Tao Zhong; Dan Xu; Wenchao Li Introduction: Limited studies report anxiety and depression prevalence and their correlations with prognosis in acute myeloid leukemia (AML). Even worse, their risk factors for AML remained unclear. This study aimed to investigate the prevalence, risk factors...

...Franziska Wachter; Yana Pikman Background: Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation...

...Karen-Sue Carlson; Ashley Cunningham; Maximilian Stahl; Eric Winer; Laura C. Michaelis Background: The classification of acute myeloid leukemia (AML) has long been overseen by the World Health Organization (WHO) and published into a series of “Blue Books.” These ledgers serve as the reference...

...Jeremy DiGennaro; David A. Sallman Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by uncontrolled proliferation and impaired differentiation of myeloid cells in the bone marrow. The tumor suppressor gene TP53 plays a crucial role in maintaining...

...Justin D. Woods; Heidi D. Klepin Background: Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults, ranging from less intensive chronic therapies to intensive...

...Amanda L. Blackmon; Christopher S. Hourigan Background: Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Acute myeloid leukemia Novel therapies Measurable residual disease TP53...

... therapies for acute myeloid leukemia (AML) have not yet been described. Methods: Through retrospective review of 19,432 patients diagnosed with acute/chronic leukemia or myelodysplastic syndromes/myeloproliferative neoplasms (MDS+/−MPN) over 28 years, we calculated the incidence of SS in the setting...

...Mu-Nan Zhao; Long Su; Fei Song; Zhi-Feng Wei; Tian-Xue Qin; Yun-Wei Zhang; Wei Li; Su-Jun Gao Introduction: Acute myeloid leukemia (AML) with internal tandem duplication (ITD) mutations in Fms-like tyrosine kinase 3 (FLT3) has an unfavorable prognosis. Recently, using newly emerging inhibitors...

...Shira Buchrits; Ofir Wolach Background: Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging, high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic, epigenetic, and metabolic events that drive clonal progression and the advent of novel therapies...

.... The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation Donor lymphocyte...

...Dahniel Sastow; Grace Van Hyfte; Jonathan Feld; Marina Kremyanskaya; John Mascarenhas; Douglas Tremblay Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However...

...Soyoung Bae; Seungwon Sa; Silvia Park; Byung-Sik Cho; Hee-Je Kim The recently approved BCL2 inhibitor venetoclax (VEN) has achieved promising outcomes in new and relapsed/refractory (R/R) acute myeloid leukemia (AML). Although its use is not well established in R/R AML with extramedullary disease...

...Jose Tinajero; Dat Ngo; Amandeep Salhotra; Paul Koller Intensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analog. In patients who cannot tolerate an anthracycline due to comorbidities, one...